Fig. 7: Pharmacological elimination of APCs in eWAT improves obesity-related metabolic impairments.
a–g DIO mice were treated with D-WAT (8 mg per mouse) or same dosage of saline. Three days later, about 4×104 CD9- APCs were sorted from DIO mice and transplanted in situ into bilateral eWAT of D-WAT-treated mice. Two weeks after treatment, metabolic parameters were analyzed. Levels of FFA (a) and glycerol (b) in serum of DIO mice (n = 7 per group). c Glucose tolerance test (n = 5 per group). d Insulin tolerance test (n = 5 per group). e–g APC subpopulations in mouse eWAT of three groups were detected by flow cytometry (e) and quantified (f,g) (n = 5 per group). g Representative images showing the staining of APCs in mouse eWAT of three groups. White arrows indicate typical stained cells. i–s Db/db mice were treated with D-WAT (8 mg per mouse) or same dosage of saline. Normoglycemic control db/+ mice were also injected with saline. Three days after D-WAT treatment, about 3.5×104 CD9-APCs were sorted from db/db mice and transplanted in situ into bilateral eWAT of D-WAT-treated mice. Four weeks after treatment, metabolic parameters were analyzed. Levels of FFA (i) and glycerol (j) in serum of db/db and control mice (n = 8 per group). k Glucose tolerance test (n = 5 per group). l Insulin tolerance test (n = 5 per group). m,n fasting blood glucose levels (m) and nonfasting blood glucose (n) in db/db and control mice (n = 8 per group). o Pyruvate tolerance test (n = 5 per group). p–r APC subpopulations in mouse eWAT of four groups were detected by flow cytometry (p) and quantified (q, r) (n = 5 per group). s Representative images showing the staining of APCs in mouse eWAT of four groups. White arrows indicate typical stained cells. Data are means ± SD. For statistical analysis, One-way ANOVA was used followed by Tukey’s multiple comparison test. Source data are provided as a Source data file.
